SUPN
SUPERNUS PHARMACEUTICALS, INC.
Next earnings Aug 3, 2026 · consensus $0.44 EPS, $209M rev
Last earnings +1.2% on 2026-05-05
$44.75
▼ -0.86%$44.75▲ +38.63%
over 1Y
L $31.16EODHDH $57.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.9%
1W+0.8%
1M-6.3%
3M-11.9%
YTD-9.5%
1Y+38.6%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Revenue grew 8.6% YoY; but unprofitable (net margin -5.4%).
SUPERNUS PHARMACEUTICALS, INC. shows $719M in FY2025 revenue (+8.6% YoY), a -5.4% net margin, and -3.6% ROE.
Sources: SEC EDGAR (CIK 0001356576, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 11:32:32 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.